Procanbid (procainamide hydrochloride extended-release tablets)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Procanbid has been approved for the treatment of ventricular
arrhythmias. While other procainamides are designed for dosage
every six hours, patients taking Procanbid can achieve therapeutic
blood levels with dosing every 12 hours.
Procanbid is available in 500 mg and 1000 mg tablets.
Ventricular arrhythmia often arises from atypical electrical
activity in the ventricles that causes the heart to beat abnormally
and affects approximately one million people annually in the United
States. The condition is responsible for more than 80 percent of
sudden cardiac deaths (SCD). In the United States, approximately
400,000 SCDs occur each year.